Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer
NCT05372692
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
mesothelin-specific chimeric antigen receptor T cell injection
Sponsor
Weijia Fang, MD
Collaborators
[object Object]